Neuronostics
University of Exeter spinout building BioEP, a digital biomarker that reads routine EEG recordings to help diagnose epilepsy.
Last refreshed: 14 July 2026 · Appears in 1 active topic
Can an EEG biomarker win FDA clearance and change epilepsy diagnosis?
Timeline for Neuronostics
Mentioned in: Five seed rounds stir beneath megadeals
UK Startups and InnovationRaised GBP3m for its BioEP epilepsy biomarker
UK Startups and Innovation: Exeter spinout raises GBP3m for epilepsyWhat is BioEP?
Who founded Neuronostics?
How much did Neuronostics raise for BioEP?
Background
Neuronostics raised GBP3 million on 30 June 2026 for BioEP, its digital epilepsy biomarker, co-led by Empirical Ventures and The FSE Group with British Business Bank, blended with a GBP400,000 Innovate UK Investor Partnerships grant.
Spun out of the University of Exeter in 2018 by Professor John Terry and Dr Wessel Woldman, the company built BioEP to extract diagnostic features from routine EEG recordings that are invisible to standard clinical review, helping neurologists judge how likely a patient is to have epilepsy. An earlier seed round backed by the Ascension Life Fund and a syndicate including QantX and Science Angels funded the platform's initial development.
Blending equity and Innovate UK grant funding in the same round lets Neuronostics push toward UK and Middle East market access while pursuing FDA clearance in the US, at a time when EEG-reading AI tools are drawing fresh clinical and investor interest across neurology.
